Table 4 Comparison of the clinical and immunological characteristics according to the genotype of F2RL1 -149C/G

Age (y) (median [IQR])

38.5 (30–51.7)

42.0 (28–53)

Sex-Female (n[%])

34 (56.7%)

11 (78.6%)

BMI (kg/m2) (median [IQR])

26.9(22.9–30.7)

28.3 (24.5–38.4)

History of smoking (n[%])

15 (25%)

9 (64.3%)

FEV₁ (% predicted) (median [IQR])

85.5 (68–92.7)

90-(75–95)

FEV₁/FVC (% predicted) (median [IQR])

83.0 (67.2–88.7)

79(70.7–8420)

IgE* (kU/L) (median [IQR])

1.71 (1.1–2.2)

2.03 (1.56–2.21)

Eosinophils** (cells/µl)

250 (177–500)

200 (100–370)

Proportion of TH2 cells/WBC^#

0.24 (0.15–0.43)

0.32 (0.16–0.49)

PAR-2 mRNA^##Expression (copies/1000 GAPDH copies)

15.7 (7.0–26.5)

26.61 (19.6–34.8)

Percentage of IMMo expressing PAR-2^&

15.4 (6.68–32.35)

8.7 (6.92–29.30)

Percentage of CMo expressing PAR-2^&&

5.5 (1.72–14.95)

7.7 (1.50–12.20)

CCL5 (ng/ml)^¶

50.0 (37.26–77.68)

44.12 (26.85–69.57)

PGD2 (pg/ml)^∞

388.45 (157.30–868.37)

285.55 (71.28–485.26)

IL-13 (pg/ml)^€

4.75 (1.0–19.10)

1.0 (1.0–22.77)